<DOC>
	<DOCNO>NCT01489969</DOCNO>
	<brief_summary>This phase II study . It conduct use randomize , double-blind , 3-arm placebo control , parallel group design . Eligible patient randomize 1:1:1 ratio receive Neu-P11 20 mg , Neu-P11 50 mg placebo 4 week The objective study assess efficacy Neu-P11 ( 20 50mg ) sleep continuity parameter insomnia patient age 18-80 year , follow first two night ( immediate effect ) end 4 week double-blind treatment . The primary efficacy endpoint study Latency Persistent Sleep ( LPS ) measure polysomnogram ( PSG ) first two night treatment ( night 15-16 study ; mean two consecutive night recording ) . The secondary endpoint number awakening sleep onset duration wake sleep onset measure PSG first two night treatment ( night 15-16 study ; mean two consecutive night recording ) .</brief_summary>
	<brief_title>Sleep Laboratory Study Investigate Safety Efficacy Neu-P11 Primary Insomnia Patients</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>1 . Male female age 1880 year ( age include ) . 2 . Suffering primary insomnia accord DSMIV criterion ( 307.42 primary insomnia , Appendix 25.1 ) ( base Sleep History Questionnaire ( SHQ ) give patient Visit Day 0 , Appendix 25.1 ) . 3 . Reported subjective sleep latency least 30 minute least three night per week least one month subjective WASO least 45 minute per night least 3 night per week least one month ( base SHQ ) . 4 . Subjects habitual bed time within range 21:0001:00 ( inclusive ) , report subject screening Day 0 . 5 . If female childbearing potential , use reliable method contraception entire study duration least 3 month study drug intake . 6 . Have use benzodiazepine ( BZD ) nonBZD hypnotic melatoninergic drug past 2 week prior Screening . 7 . Have use psychotropic treatment past 3 month prior Screening . 8 . Are stabilized nonpsychotropic treatment 3 month prior Screening . 9 . Are willing sign write informed consent participate study . • After initial screening , recruit patient enter 2 week placebo baseline/eligibility period . Patients admit sleep lab continue double blind treatment phase polysomnography ( PSG ) result meet following criterion : 10 . Mean LPS ≥30 minute PSG screen night , neither night &lt; 15 minute . 11 . Mean total sleep time ( TST ) ≤390 minute , mean WASO ≥30 minute 2 PSG screen night , neither night &lt; 15 minute . 1 . According DSM IV , subject belong follow group exclude : 780.59 ( breathe relate sleep disorder ) ; 307.45 ( circadian rhythm sleep disorder ) ; 307.47 ( dyssomnia otherwise specify ) ; 780.xx ( sleep disorder due general medical condition ) 2 . Subjects suffer insomnia secondary cause accord sleep history questionnaire . 3 . Subjects sleep disorder detect PSG inclusion/habituation night , sleep apnea/hypopnea periodic leg movement syndrome ( arousal ) ( PLMAI &gt; 10 and/or AHI &gt; 10 per hour ) . 4 . Use psychotropic treatment past 3 month study . 5 . Use strong CYP inhibitor precede 3 month study 6 . Use benzodiazepines hypnotic precede two week ( include benzodiazepine ; zopiclone , zolpidem , zaleplon , barbiturate , buspirone hydroxyzine ) . 7 . Alcohol intake 2 alcoholic drink per day consumption le 2 hour study drug intake . 8 . Immunosuppressive medication precede 3 month study 9 . Severe neurological , psychiatric disorder especially psychosis , anxiety depression 10 . Intercurrent acute chronic somatic disease likely interact sleep ( example : chronic pain etiology , benign prostatic hypertrophy likely require surgery come six month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>sleep latency</keyword>
	<keyword>Sleep maintenance</keyword>
	<keyword>Sleep fragmentation</keyword>
	<keyword>Polysomnography</keyword>
</DOC>